Literature DB >> 8974865

Novel anticoagulants for flow cytometric analysis of live leucocytes in whole blood.

D A McCarthy1, M G Macey.   

Abstract

Enzyme inhibitors have been compared with conventional anticoagulants for the flow cytometric analysis of live leucocytes in whole blood. At 18 to 20 degrees C in vitro, PPACK (60 microM), hirudin (10 units ml-1), leupeptin (20 microg ml-1) and aprotinin (50 microg ml-1) inhibited blood clotting for 4 h or more, whereas PMSF (8 mg ml-1) or AEBSF (5 mg ml-1) inhibited clotting for only 20 or 40 min, respectively. When labelled with CD11b antibodies and analysed immediately ex vivo at 4 degrees C, the percentages of lymphocytes, monocytes, and polymorphs which stained positively and their mean fluorescence intensities were similar, irrespective into which anticoagulant blood was collected. Less than 1.5-fold increases in expression occurred on monocytes and polymorphs when blood anticoagulated with enzyme inhibitors or conventional anticoagulants was kept at 4 degrees C, or when blood anticoagulated with citrate, heparin, or hirudin was kept at 18 to 20 degrees C for 1 h before labelling and analysis, whereas approximately 2-fold increases in expression occurred in blood kept with K3EDTA, leupeptin, or aprotinin and more than 3-fold increases in blood kept with AEBSF or PPACK at 18 to 20 degrees C for 1 h. Further studies showed that leupeptin could be used effectively as the anticoagulant when investigating functional responses of live leucocytes in whole blood samples by flow cytometry and for the isolation of leucocytes with minimal modulation of adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8974865     DOI: 10.1002/(SICI)1097-0320(19960301)23:3<196::AID-CYTO3>3.0.CO;2-H

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  6 in total

1.  Adhesion molecules are upregulated on dendritic cells isolated from human blood.

Authors:  D A McCarthy; M G Macey; P A Bedford; S C Knight; D C Dumonde; K A Brown
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

2.  Evidence of changes in the immunophenotype and metabolic characteristics (intracellular reactive oxygen radicals) of fetal, but not maternal, monocytes and granulocytes in the fetal inflammatory response syndrome.

Authors:  Sun Kwon Kim; Roberto Romero; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Pooja Mittal; Offer Erez; Edi Vaisbuch; Francesca Gotsch; Percy Pacora; Lami Yeo; Maria Teresa Gervasi; Ronald F Lamont; Bo Hyun Yoon; Sonia S Hassan
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

3.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

4.  Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia.

Authors:  Giovanna Oggé; Roberto Romero; Tinnakorn Chaiworapongsa; Maria Teresa Gervasi; Percy Pacora; Offer Erez; Juan Pedro Kusanovic; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Pooja Mittal; Yeon Mee Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-06

Review 5.  Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?

Authors:  T Michael De Silva; Alyson A Miller
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

6.  Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels.

Authors:  Łukasz Sędek; Juan Flores-Montero; Alita van der Sluijs; Jan Kulis; Jeroen Te Marvelde; Jan Philippé; Sebastian Böttcher; Marieke Bitter; Joana Caetano; Vincent H J van der Velden; Edwin Sonneveld; Chiara Buracchi; Ana Helena Santos; Margarida Lima; Tomasz Szczepański; Jacques J M van Dongen; Alberto Orfao
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.